VRNA Verona Pharma ADS

Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China

Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China

LONDON and RALEIGH, N.C., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces its development partner, Nuance Pharma, has received clearance from the Center of Drug Evaluation (“CDE”) for its Investigational New Drug (“IND”) application to conduct both Phase 1 and Phase 3 studies with ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (“COPD”) in mainland China.

In 2021, Nuance Pharma entered into an agreement with Verona Pharma with a potential value of up to $219 million, granting Nuance Pharma exclusive rights to develop and commercialize ensifentrine in Greater China (mainland China, Hong Kong, Macau and Taiwan). In return, Verona Pharma received an upfront payment of $25 million in cash and an equity interest valued at $15 million in Nuance Biotech, the parent company of Nuance Pharma. In addition, Verona Pharma is eligible to receive future milestone payments as well as double-digit royalties as a percentage of net sales in Greater China.

“We are pleased our development partner, Nuance Pharma, has received IND approval to begin pivotal studies in COPD with ensifentrine in mainland China,” said David Zaccardelli, Pharm. D., President and Chief Executive Officer of Verona Pharma. “This is an important milestone and, based on our recent positive Phase 3 results from our ENHANCE-2 trial in COPD, we remain confident about the potential of ensifentrine to address the urgent global need for a novel treatment for COPD.”

For further information please contact:

  
Verona Pharma plcUS Tel:



UK Tel: +44 (0)203 283 4200
Victoria Stewart, Director of Investor Relations and Communications
  
Argot Partners

(US Investor Enquiries)
Tel:

Kimberly Minarovich / Michael Barron 
  
Optimum Strategic Communications

(International Media and European Investor Enquiries)
Tel: +44 (0)203 882 9621

Mary Clark / Rebecca Noonan / Zoe Bolt 

About Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Ensifentrine met the primary endpoint in ENHANCE-2 demonstrating a statistically significant and clinically meaningful improvement in lung function. In addition, ensifentrine significantly reduced the rate of COPD exacerbations in the ENHANCE-2 trial. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit .

About Nuance Pharma

Nuance Pharma is a patient-centric and innovation focused biopharmaceutical company, with both clinical and commercial stage assets. Founded by Mark Lotter in 2014, with the mission to address critical unmet medical needs in Greater China and Asia Pacific, Nuance's portfolio represents a differentiated combination of commercial stage and innovative pipeline assets across respiratory, pain management, emergency care and iron deficiency anemia. Focusing on specialty care, Nuance deploys the Dual Wheel model that incubates a late clinical stage innovative portfolio, while maintaining a self-sustainable commercial operation.

Forward-Looking Statements

This press release contains forward-looking statements. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding milestone payments, royalties and other financial terms of the collaboration agreement with Nuance Pharma, the timing of Nuance Pharma beginning clinical studies for the treatment of COPD in China, and the potential of ensifentrine in the treatment of COPD, cystic fibrosis, asthma and other respiratory diseases.

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from our expectations expressed or implied by the forward-looking statements including, but not limited to, the following: our limited operating history; the reliance of our business on the success of ensifentrine, our only product candidate under development; economic, political, regulatory and other risks involved with international operations; the lengthy and expensive process of clinical drug development, which has an uncertain outcome; serious adverse, undesirable or unacceptable side effects associated with ensifentrine, which could adversely affect our ENHANCE Phase 3 program or our ability to develop or commercialize ensifentrine; potential delays in enrolling patients, which could adversely affect our or Nuance Pharma’s research and development efforts and the completion of our or Nuance Pharma’s clinical trials; we may not be successful in developing ensifentrine for multiple indications; misconduct or other improper activities by our employees, consultants, principal investigators, third-party service providers or development partners; our future growth and ability to compete depends on retaining our key personnel and recruiting additional qualified personnel; material differences between our “top-line” data and final data; our reliance on third parties, including clinical research organizations, clinical investigators, manufacturers and suppliers, and the risks related to these parties’ ability to successfully develop and commercialize ensifentrine; and lawsuits related to patents covering ensifentrine and the potential for our patents to be found invalid or unenforceable; and our vulnerability to natural disasters, global economic and geo-political factors and other unexpected events, including health epidemics or pandemics like the COVID-19 pandemic, which has and may continue to adversely impact our business. These and other important factors under the caption “Risk Factors” in Verona Pharma’s Annual Report on Form 10-K filed with the SEC on March 3, 2022, and Verona Pharma’s other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, the Company disclaims any obligation to do so, even if subsequent events cause the Company’s views to change. These forward-looking statements should not be relied upon as representing Verona Pharma’s views as of any date subsequent to the date of this press release.

 



EN
19/08/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Verona Pharma ADS

Andreas Argyrides ... (+8)
  • Andreas Argyrides
  • David Nierengarten
  • Dennis Pak
  • Laura Chico
  • Liana Moussatos
  • Ritika Das
  • Robert Driscoll
  • Sam Ravina
OC OWENS CORNING INC
BLUE BLUEBIRD BIO INC.
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
SGMO SANGAMO THERAPEUTICS INC.
SAGE SAGE THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PCRX PACIRA BIOSCIENCES INC.
NVCR NOVOCURE LTD.
KPTI KARYOPHARM THERAPEUTICS
GERN GERON CORP.
FL FOOT LOCKER INC.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
CLSD CLEARSIDE BIOMEDICAL INC
ALBO ALBIREO PHARMA
ANAB ANAPTYSBIO INC.
KALA KALA PHARMACEUTICALS INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
ALPN ALPINE IMMUNE SCIENCES
VRNA VERONA PHARMA ADS
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
SURF SURFACE ONCOLOGY
UBX UNITY BIOTECHNOLOGY
AVRO AVROBIO
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
MGTA MAGENTA THERAPEUTICS
AX AXOS FINANCIAL INC.
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
HARP HARPOON THERAPEUTICS
ISEE IVERIC BIO
IMUX IMMUNIC INC
BCEL ATRECA
C TEST
AXLA AXCELLA HEALTH
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
AQST AQUESTIVE THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
KDNY CHINOOK THERAPEUTICS
PASG INC.
BDTX PASSAGE BIO
ACET BLACK DIAMOND THERAPEUTICS
FRLN ADICET BIO INC
ITOS FREELINE THERAPEUTICS HOLDINGS ADS
INZY ITEOS THERAPEUTICS
CDAK INOZYME PHARMA
ZNTL CODIAK BIOSCIENCES
BEAM INC.
PRAX ZENTALIS PHARMACEUTICALS
COGT BEAM THERAPEUTICS
TVTX PRAXIS PRECISION MEDICINES
KNTE COGENT BIOSCIENCES INC
VRDN TRAVERE THERAPEUTICS INC
VOR KINNATE BIOPHARMA
DAWN VIRIDIAN THERAPEUTICS INC
ELEV VOR BIOPHARMA
FHTX DAY ONE BIOPHARMACEUTICALS INC
TNGX ELEVATION ONCOLOGY
LBPH FOGHORN THERAPEUTICS
THRX TANGO THERAPEUTICS
VERA INC
TSVT LONGBOARD PHARMACEUTICALS
IMPL THESEUS PHARMACEUTICALS
DSGN INC.
TCRR VERA THERAPEUTICS INC
ATXS 2SEVENTY BIO INC
RANI IMPEL NEUROPHARMA INC
AVTE DESIGN THERAPEUTICS INC
CMPX TCR2 THERAPEUTICS INC
KRTX ASTRIA THERAPEUTICS INC
FUSN RANI THERAPEUTICS HLDGS INC
VIGL AEROVATE THERAPEUTICS INC
EWTX COMPASS THERAPEUTICS
BOLD KARUNA THERAPEUTICS INC
FUSION PHARMACEUTICALS INC
VIGIL NEUROSCIENCE INC
EDGEWISE THERAPEUTICS INC
AUDENTES THERAPEUTICS
Wedbush Research
  • Wedbush Research
2454 MEDIA TEK INC
VMW VMWARE INC. CLASS A
QRVO QORVO INC.
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SAGE SAGE THERAPEUTICS INC.
QCOM QUALCOMM INC
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NVCR NOVOCURE LTD.
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
FB FACEBOOK INC. CLASS A
FATE FATE THERAPEUTICS INC
EWBC EAST WEST BANCORP INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
AMC AMC ENTERTAINMENT HOLDINGS INC. CLASS A
WD WALKER & DUNLOP INC.
SWKS SKYWORKS SOLUTIONS INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
HPE HEWLETT PACKARD ENTERPRISE CO.
CLSD CLEARSIDE BIOMEDICAL INC
NTLA INTELLIA THERAPEUTICS INC.
ALBO ALBIREO PHARMA
MRSN MERSANA THERAPEUTICS
GTHX G1 THERAPEUTICS
VRNA VERONA PHARMA ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
APLS APELLIS PHARMACEUTICALS
RCUS ARCUS BIOSCIENCES
AVGO BROADCOM INC.
SURF SURFACE ONCOLOGY
SRRK SCHOLAR ROCK HOLDING CORPORATION
LQDA LIQUIDIA CORPORATION
AX AXOS FINANCIAL INC.
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
DELL DELL TECHNOLOGIES INC CLASS C
IGMS IGM BIOSCIENCES
SMCI SUPER MICRO COMPUTER
SI INC.
PASG SILVERGATE CAPITAL
ACET PASSAGE BIO
ITOS ADICET BIO INC
CDAK ITEOS THERAPEUTICS
ZNTL CODIAK BIOSCIENCES
VOR INC.
NUVB ZENTALIS PHARMACEUTICALS
FHTX VOR BIOPHARMA
TNGX NUVATION BIO INC (A)
MRVL FOGHORN THERAPEUTICS
STX TANGO THERAPEUTICS
TSVT INC
TCRR MARVELL TECHNOLOGY INC
GFS SEAGATE TECHNOLOGY HLDGS PLC
2SEVENTY BIO INC
TCR2 THERAPEUTICS INC
GLOBALFOUNDRIES INC
Wedbush Research
  • Wedbush Research
2454 MEDIA TEK INC
INFY INFOSYS LIMITED
W9N WNS (HOLDINGS) LIMITED SPONSORED ADR
WING WINGSTOP INC.
WEN WENDY'S COMPANY
WDC WESTERN DIGITAL CORPORATION
UMH UMH PROPERTIES INC.
TSLA TESLA INC
SQ SQUARE INC. CLASS A
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
QCOM QUALCOMM INC
PYPL PAYPAL HOLDINGS INC
PSTG PURE STORAGE INC. CLASS A
PANW PALO ALTO NETWORKS INC.
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
JACK JACK IN THE BOX INC.
INTC INTEL CORPORATION
35G GENPACT LIMITED
FRC FIRST REPUBLIC BANK
EXLS EXLSERVICE HOLDINGS INC.
DKS DICK'S SPORTING GOODS INC.
DIN DINE BRANDS GLOBAL INC.
CXW CORECIVIC INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
CFG CITIZENS FINANCIAL GROUP INC.
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
CLSD CLEARSIDE BIOMEDICAL INC
RDFN REDFIN CORPORATION
VRNA VERONA PHARMA ADS
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
AVGO BROADCOM INC.
PRPL PURPLE INNOVATION
UBX UNITY BIOTECHNOLOGY
TENB TENABLE HOLDINGS
SMCI SUPER MICRO COMPUTER
APRE INC.
SI APREA THERAPEUTICS
PRAX SILVERGATE CAPITAL
U PRAXIS PRECISION MEDICINES
RBLX UNITY SOFTWARE
RMBL ROBLOX
FHTX RUMBLEON INC
MRVL FOGHORN THERAPEUTICS
STX MARVELL TECHNOLOGY INC
APP SEAGATE TECHNOLOGY HLDGS PLC
FLYW APPLOVIN CORP
PAY FLYWIRE CORP
IMGO PAYMENTUS HLDGS INC
MQ IMAGO BIOSCIENCES INC
RIVN MARQETA INC
GFS RIVIAN AUTOMOTIVE INC
CMPX GLOBALFOUNDRIES INC
TOST COMPASS THERAPEUTICS
TOAST INC
Andreas Argyrides ... (+2)
  • Andreas Argyrides
  • Liana Moussatos

ResearchPool Subscriptions

Get the most out of your insights

Get in touch